Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc.

In a report released today, Maxwell Skor from Morgan Stanley maintained a Hold rating on Atea Pharmaceuticals, with a price target of $4.10. Accord...

Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (AGIO) and Atea Pharmaceuticals (AVIR) ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$4.19	+0.96%	211.62K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$4.19	+1.0%	211.62K
3
4
5
6

AVIR

AVIR

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel